Efficient Differentiation of Mouse Embryonic Stem Cells into Insulin-Producing Cells

Szu-Hsiu; Liu Lee; Lain-Tze Lee
January 2012
Experimental Diabetes Research;2012, Special section p1
Academic Journal
Embryonic stem (ES) cells are a potential source of a variety of differentiated cells for cell therapy, drug discovery, and toxicology screening. Here, we present an efficacy strategy for the differentiation of mouse ES cells into insulin-producing cells (IPCs) by a two-step differentiation protocol comprising of (i) the formation of definitive endoderm in monolayer culture by activin A, and (ii) this monolayer endoderm being induced to differentiate into IPCs by nicotinamide, insulin, and laminin. Differentiated cells can be obtained within approximately 7 days. The differentiation IPCs combined application of RT-PCR, ELISA, and immunofluorescence to characterize phenotypic and functional properties. In our study, we demonstrated that IPCs produced pancreatic transcription factors, endocrine progenitor marker, definitive endoderm, pancreatic β-cell markers, and Langerhans a and d cells. The IPCs released insulin in a manner that was dose dependent upon the amount of glucose added. These techniques may be able to be applied to human ES cells, which would have very important ramifications for treating human disease.


Related Articles

  • Engineered embryonic stem cells for regnerative nedicine. Hescheler, J. // Cell Research;Aug2008 Supplement, Vol. 18, pS111 

    Due to their ability to reproduce the embryological differentiation of nearly all different cellular phenotypes, embryonic stem (ES) cells represent an ideal tool to study processes of embryogenesis under in vitro conditions, in particular the signalling cascades and genes involved in the...

  • Umbilical Cord Blood: A Unique Source of Pluripotent Stem Cells for Regenerative Medicine. Harris, David T.; Rogers, Ian // Current Stem Cell Research & Therapy;Dec2007, Vol. 2 Issue 4, p301 

    It is estimated that almost 1 in 3 individuals in the United States might benefit from regenerative medicine therapy. Unfortunately, embryonic stem (ES) cell therapies are currently limited by ethical, political, biological and regulatory hurdles. Thus, for the foreseeable future, the march of...

  • Safer Way to Produce Stem Cell Alternative Demonstrated. ANDRUSKO, DAVE // National Right to Life News;Mar2009, Vol. 36 Issue 3, p12 

    The article discusses research being done on a new way to more safely reprogram adult stem cells which can provide a virtually limitless supply of embryonic-like stem cells called induced pluripotent stem (iPS) cells. It references studies by Andras Nagy and Keisuke Kaji, published in "Nature."...

  • iPS and ES Cells: Do Both Roads Lead to Rome? Ng, Valerie Y.; Choo, Andre B. H. // Open Stem Cell Journal;2010 Special Issue, p8 

    The seminal report from Takahashi and Yamanka in 2006 describing the reprogramming of somatic cells to induced pluripotent stem (iPS) cells [1] marked the beginning of a new field of research, resulting in hundreds of publications in a short 3 years. Among other things, the promise of iPS cells...

  • The Bioethics of Human Pluripotent Stem Cells: Will Induced Pluripotent Stem Cells End the Debate? Watt, Julia C.; Kobayashi, Nao R. // Open Stem Cell Journal;2010 Special Issue, p18 

    The ethical debate surrounding human pluripotent stem (PS) cell research is mainly due to use of human embryonic stem (ES) cells. It has been suggested by many that human induced pluripotent stem (iPS) cells would end the debate due to their non-embryonic origin. This review examines the ethical...

  • Cell therapy in the heart. Abdelli, Latifa S.; Merino, Hilda; Rocher, Crystal M.; Singla, Dinender K. // Canadian Journal of Physiology & Pharmacology;Mar2012, Vol. 90 Issue 3, p307 

    Cell therapy is emerging as a new strategy to circumvent the adverse effects of heart disease. Many experimental and clinical studies investigating the transplantation of cells into the injured myocardium have yielded promising results. Moreover, data from these reports show that transplanted...

  • Development of embryonic stem cells in recombinant kidneys. Rak-Raszewska, Aleksandra; Wilm, Bettina; Edgar, David; Kenny, Simon; Woolf, Adrian S.; Murray, Patricia // Organogenesis;Oct-Dec2012, Vol. 8 Issue 4, p125 

    Embryonic stem cells (ESC) are self-renewing and can generate all cell types during normal development. previous studies have begun to explore fates of ESCs and their mesodermal derivatives after injection into explanted intact metanephric kidneys and neonatal kidneys maturing in vivo. here, we...

  • Nuclear Magnetic Resonance Detects Phosphoinositide 3-Kinase/Akt-Independent Traits Common to Pluripotent Murine Embryonic Stem Cells and Their Malignant Counterparts. Romanska, Hanna M.; Tiziani, Stefano; Howe, Rachael C.; Günther, Ulrich L.; Gulzar, Zulfiqar; Lalani, El-Nasir // Neoplasia;Dec2009, Vol. 11 Issue 12, p1301 

    Pluripotent embryonic stem (ES) cells, a potential source of somatic precursors for cell therapies, cause tumors after transplantation. Studies of mammalian carcinogenesis using nuclear magnetic resonance (NMR) spectroscopy have revealed changes in the choline region, particularly increased...

  • Suspension Culture of Undifferentiated Human Embryonic and Induced Pluripotent Stem Cells. Amit, Michal; Chebath, Judith; Margulets, Victoria; Laevsky, Ilana; Miropolsky, Yael; Shariki, Kohava; Peri, Meital; Blais, Idit; Slutsky, Guy; Revel, Michel; Itskovitz-Eldor, Joseph // Stem Cell Reviews & Reports;Jun2010, Vol. 6 Issue 2, p248 

    Alongside their contribution to research, human embryonic stem cells (hESC) may also prove valuable for cell-based therapies. Traditionally, these cells have been grown in adhesion culture either with or without feeder cells, allowing for their continuous growth as undifferentiated cells....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics